BioScience Health Innovations Reports Zero Revenue, Narrows Q2 Loss

TL;DR

**BHIC is a pre-revenue biotech gamble, only for the bold who believe in future innovation, not current financials.**

AI Summary

BioScience Health Innovations, Inc. (BHIC) reported no revenue for the quarter ended June 30, 2025, consistent with its prior period. The company incurred a net loss of $10,000 for the three months ended June 30, 2025, compared to a net loss of $15,000 for the same period in 2024, representing a 33.3% improvement in net loss. Key business changes include the company's continued focus on developing its health innovations, though specific product details or milestones were not disclosed in this filing. Risks primarily revolve around its early-stage development and lack of revenue generation, indicating a high dependency on future capital raises. The strategic outlook remains centered on product development and eventual commercialization, with no immediate plans for revenue generation or profitability. The company's cash balance was not explicitly stated, but the net loss suggests ongoing operational expenses without offsetting income.

Why It Matters

For investors, BHIC's continued lack of revenue and early-stage status signal high risk and speculative potential, making it suitable only for those with a high-risk tolerance. Employees face uncertainty given the company's pre-revenue stage and reliance on future funding. Customers are not yet impacted as there are no commercialized products. In the broader market, BHIC's status as a 'smaller reporting company' and 'emerging growth company' highlights the challenges faced by nascent biotech firms in a competitive landscape dominated by established players like Johnson & Johnson or Pfizer, which have significant R&D budgets and market share.

Risk Assessment

Risk Level: high — The risk level is high because BioScience Health Innovations, Inc. reported no revenue for the quarter ended June 30, 2025, and incurred a net loss of $10,000. This indicates a complete lack of operational income and reliance on external funding, characteristic of an early-stage company with significant uncertainty regarding future viability and profitability.

Analyst Insight

Investors should approach BHIC with extreme caution, recognizing it as a highly speculative investment. Due diligence should focus on any future product development announcements or funding rounds, as current financials offer no basis for valuation. Consider a very small, diversified position if you have a high-risk appetite and believe in the long-term potential of its undisclosed innovations.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the quarter ended June 30, 2025, indicating pre-commercialization stage.)
• $10,000 — Net Loss (Q2 2025) (Represents the net loss for the three months ended June 30, 2025, showing ongoing operational expenses.)
• $15,000 — Net Loss (Q2 2024) (Net loss for the prior year's comparable quarter, indicating a 33.3% reduction in net loss year-over-year.)
• 33.3% — Net Loss Improvement (Percentage reduction in net loss from Q2 2024 to Q2 2025, from $15,000 to $10,000.)
• 7374 — SIC Code (Primary Standard Industrial Classification for 'SERVICES-COMPUTER PROCESSING & DATA PREPARATION', which may not accurately reflect a 'health innovations' company.)

Key Players & Entities

• BioScience Health Innovations, Inc. (company) — registrant in the 10-Q filing
• $10,000 (dollar_amount) — net loss for the three months ended June 30, 2025
• $15,000 (dollar_amount) — net loss for the three months ended June 30, 2024
• June 30, 2025 (date) — end of the quarterly reporting period
• Nevada (location) — state of incorporation for BHIC
• Salt Lake City, UT (location) — principal executive offices of BHIC
• SEC (regulator) — Securities and Exchange Commission
• Nowtransit Inc (company) — former name of BioScience Health Innovations, Inc.

FAQ

Risk Factors

• Lack of Revenue and Profitability [high — financial]: The company reported $0 revenue for the quarter ended June 30, 2025, and incurred a net loss of $10,000. This indicates a complete reliance on external funding for operations and development, posing a significant financial risk.
• Early-Stage Development Dependency [high — operational]: BHIC's business model is centered on developing health innovations. The lack of disclosed product milestones or specific development progress in the 10-Q suggests that the company's success is entirely dependent on the future outcomes of these early-stage research and development efforts.
• Capital Raise Dependency [high — financial]: Given the ongoing net losses and absence of revenue, the company is highly dependent on future capital raises to sustain its operations and fund its development pipeline. Failure to secure additional financing could lead to cessation of operations.
• Unclear Business Focus [medium — operational]: The company's SIC code is 'SERVICES-COMPUTER PROCESSING & DATA PREPARATION' (7374), which appears misaligned with its stated focus on 'health innovations'. This discrepancy raises questions about the clarity and execution of its core business strategy.

Industry Context

The health innovations sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often operate at a loss for extended periods, relying heavily on venture capital or public markets for funding until a product achieves commercialization and generates revenue.

Regulatory Implications

As a company in the health innovations space, BHIC is subject to stringent regulatory oversight from bodies like the FDA. Delays in product development or failure to meet regulatory standards can significantly impact timelines and the ability to bring products to market, posing a substantial risk.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the latest financial and operational details for BioScience Health Innovations, Inc. for the period ending June 30, 2025.)

SIC Code

Standard Industrial Classification code, a four-digit number used by U.S. government agencies to classify businesses by industry. (The SIC code 7374 ('SERVICES-COMPUTER PROCESSING & DATA PREPARATION') for BHIC appears inconsistent with its stated business of health innovations, potentially indicating a mismatch in reporting or business focus.)

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (BHIC reported a net loss of $10,000 for Q2 2025, highlighting its current lack of profitability and ongoing operational costs.)

Year-Over-Year Comparison

BioScience Health Innovations, Inc. reported $0 revenue for the quarter ended June 30, 2025, consistent with the prior year's period. The company significantly improved its financial performance by reducing its net loss by 33.3%, from $15,000 in Q2 2024 to $10,000 in Q2 2025. No new material risks were explicitly detailed in this filing, but the existing risks related to early-stage development and lack of revenue remain prominent.

From the Filing

0001185185-25-000908.txt : 20250807 0001185185-25-000908.hdr.sgml : 20250807 20250807123001 ACCESSION NUMBER: 0001185185-25-000908 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioScience Health Innovations, Inc. CENTRAL INDEX KEY: 0001784440 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] ORGANIZATION NAME: 06 Technology EIN: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-234487 FILM NUMBER: 251192744 BUSINESS ADDRESS: STREET 1: 2722 S WEST TEMPLE CITY: SALT LAKE CITY STATE: UT ZIP: 84115 BUSINESS PHONE: 801-949-0791 MAIL ADDRESS: STREET 1: 2722 S WEST TEMPLE CITY: SALT LAKE CITY STATE: UT ZIP: 84115 FORMER COMPANY: FORMER CONFORMED NAME: Nowtransit Inc DATE OF NAME CHANGE: 20190802 10-Q 1 bhic10q063025.htm FORM 10-Q     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549         FORM 10-Q       Mark One   ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended June 30, 2025   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from                             to                              Commission File No. 333-234487   BIOSCIENCE HEALTH INNOVATIONS INC. (Exact name of registrant as specified in its charter)   Nevada   7374   98-1498782 (State or Other Jurisdiction of   (Primary Standard Industrial   (IRS Employer Incorporation or Organization)   Classification Number)   Identification Number)   2722 South West Temple Salt Lake City , UT 84115 (Address of principal executive offices)   Registrant’s telephone number, including area code: (801) 949-0791   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered None   None   None   Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.0001   Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated Filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)